Tricuspid valve: Is Percutaneous Intervention Feasible in Patients with Definite Pacemaker?

Courtesy of Dr. Carlos Fava.

As we know, with higher life expectancy comes a significant increase in the use of definite pacemakers, defibrillators and resynchronization devices. Along these lines, the presence of catheters is associated to tricuspid regurgitation, which over time might become severe, leading to cardiac regurgitation and potentially heart failure. 

¿Fin de la discusión sobre el impacto del marcapaso post TAVI?

This group is now being treated with transcatheter tricuspid valve intervention (TTVI), but little is known about its efficacy.

The study looked at 470 tricuspid regurgitation patients form the TriValve registry undergoing TTVI between January 2015 and December 2018. 121 (25.7%) of these patients presented pacemakers or defibrillators (Cardiac Implantable Electronic Device – CIED) and its evolution was compared against 349 patients with no CIED.

The groups were similar, mean age was 76, they were mostly women, with 36% atrial fibrillation, and EuroScore 10. Patients receiving CIED presented a higher number of hospitalizations, more functional class III-IV, ascites, peripheral edema, COPD, need for diuretics and higher NT pro-BNP. The most frequent cause was functional.


Read also: Plaque Morphology Could Modify Functional Measurements.


In addition, CIED patients presented lower ejection fraction, larger left ventricular diameter and area and higher pulmonary artery systolic pressure. However, effective regurgitant orifice area was smaller. 

In both groups, the device most used was the MitraClip, with 80% procedural success.

In-hospital mortality was 2.9% for the no-CIED and 3.7% for the CIED (p=0.7). 


Read also: The Most Read Scientific Articles of March.


At 30 days, there were no significant differences neither in residual tricuspid regurgitation ≤2+ (70.8 vs. 73.7%) nor in improvement to functional class I-II (66% vs. 65% p=0.3).

Survival at one year was similar (80.7% vs. 73.6% p=0.3).

Conclusion

Transcatheter tricuspid valve intervention in patients with definite pacemaker or defibrillators is feasible and has good hospital outcomes which in the short term are comparable to those of patients with no pacemakers or defibrillators. 

Courtesy of Dr. Carlos Fava.

Original Title: Outcomes of TTVI in Patients With Pacemaker or Defibrillator Leads Data From the TriValve Registry.

Reference: Maurizio Taramasso, et al. J Am coll Cardiol Intv 2020;13:554-64.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....